Veraxa Biotech AG - Post de-SPAC (VRXA) Net Cash Flow (2025)
Veraxa Biotech AG - Post de-SPAC's (VRXA) quarterly Net Cash Flow came in at $126368.1 in Q4 2025.
Powered by 
Analysis
Veraxa Biotech AG - Post de-SPAC (VRXA) Net Cash Flow (2025) Analysis & Trends
Veraxa Biotech AG - Post de-SPAC (VRXA) has reported Net Cash Flow for 1 consecutive years, with $126368.1 the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Veraxa Biotech AG - Post de-SPAC | 23.88 Mn | 20.47 Mn | - | 126,368.15 |